Anaplastic meningioma is a rare and aggressive brain tumor characterised by intractable 54 recurrences and dismal outcomes. Here, we present an integrated analysis of the whole 55 genome, transcriptome and methylation profiles of primary and recurrent anaplastic 56 meningioma. A key finding was the delineation of two distinct molecular subgroups that 57 were associated with diametrically opposed survival outcomes. Relative to lower grade 58 meningiomas, anaplastic tumors harbored frequent driver mutations in SWI/SNF complex 59 genes, which were confined to the poor prognosis subgroup. Our analyses discern two 60 biologically distinct variants of anaplastic meningioma with potential prognostic and 61 therapeutic significance. 62
Results 91
Overview of the genomic landscape of primary and recurrent anaplastic 92 meningioma 93 We performed whole genome sequencing (WGS) on a discovery set of 19 anaplastic 94 meningiomas resected at first presentation ('primary'). A subsequent validation cohort 95 comprised 31 primary tumors characterised by targeted sequencing of 366 cancer genes. 96 We integrated genomic findings with RNA sequencing and methylation array profiling in a 97 subset of samples ( Supplementary Table S1 ). Somatic copy number alterations and 98 rearrangements were derived from whole genome sequencing reads, with RNA 99 sequences providing corroborating evidence for gene fusions. Given the propensity of 100 anaplastic meningioma to recur, we studied by whole genome sequencing 13 recurrences 101 from 7 patients. 102
Excluding a hypermutated tumor (PD23359a, see Supplementary Discussion), the 103 somatic point mutation burden of meningioma was low with a median of 28 somatic 104 Recurrent large copy number changes were in keeping with known copy number trends in 117 aggressive meningiomas, notably frequent deletions affecting chromosomes 1p, 6q, 14 118 and 22q (Figure 1b , Supplementary Table S6 ) 2,8,10,13 . 119
The genomic landscape of recurrent tumors was largely static both with respect to driver 120 mutations and structural variation. Driver mutations differed between primary and 121 recurrent tumors for two of eleven patients with serial resections available. For seven sets 122 of recurrent tumors studied by whole genome sequencing, only two demonstrated any 123 discrepancies in large copy number variants (PD23344 and PD23346; Supplementary 124 Figure S5 ). Similarly, matched primary and recurrent samples clustered closely together 125 by PCA of transcriptome data, suggesting minimal phenotypic evolution (Supplementary 126 Figure S6 ). 127 Table S1 ). ARID1A has not been implicated as a driver in grade I or grade II 139 meningiomas 8, 10 . Single variants in SMARCB1, SMARCA4 and PBRM1 were also 140 detected in three tumors (Supplementary Figure S7 ). In total, 16% of anaplastic 141 meningiomas contained a SWI/SNF gene mutation. By contrast, SWI/SNF genes are 142 mutated in <5% of benign and atypical meningiomas 8, 10 . 143 In the combined cohort of 50 primary tumors, we found at least one driver mutation in 144 NF2 in 70%, similar to the prevalence reported in atypical meningiomas and more than 145 twice that found in grade I tumors 8,10,14 . Interestingly, there was no significant difference in 146 NF2 expression between NF2 mutant and wild-type tumors (p-value 0.960; 147 Supplementary Figure S8 ). We considered promoter hypermethylation as a source of 148 NF2 inactivation, but found no evidence of this ( Supplementary Table S7 ). Thus, as 149 observed in other cancer types, non-mutational mechanisms may contribute to NF2 loss 150 of function in a proportion of anaplastic meningiomas 15-20 . 151 Other driver genes commonly implicated in low grade tumors were not mutated, or very 152 infrequently (Figure 1a ). Furthermore, we did not observe an increased frequency of 153 TERT promoter mutations, previously associated with progressive or high grade 154 tumors 21,22 . Notably 2,23,24 , methylation analysis revealed CDKN2A and PTEN promoter 155 hypermethylation in 17% and 11% of primary tumors, respectively ( Figure 1a ). We did not 156 progressive tumor) (Supplementary Figure S6 ). However, multiple unsupervised 169 hierarchical clustering methods and correlation measures consistently delineated two 170 distinct clusters, hereafter referred to as C1 and C2 (Figure 2a -c). The clinical trajectories 171 of patients in these clusters markedly diverged. We retrospectively sought follow-up 172 survival data from the time of first surgery, which was available for 25 of the 28 patients 173 included in the transcriptome analysis (12 patients in C1, 13 in C2; mean follow-up of 174 1,403 days from surgery). We observed a significantly worse overall survival outcome in 175 C1 compared to C2 (p<0.0001, hazard ratio 17.0 (95% CI 5.2-56.0)) ( Figure 2g ; 176 Supplementary Table S8 ). The subgroups were well balanced with respect to potential 177 confounding features such as gender, age, radiotherapy and anatomical location 178 ( Supplementary Table S9 ). Paradoxically, a greater proportion of C2 patients had higher 179
Simpson surgical resection scores (indicating more residual tumor after surgery), 180 conventionally a negative prognostic indicator (P = 0.081, Fisher's exact test) 4,6 . 181 182 subgroups C1 and C2, which could be reduced to only 6 transcripts selected on the basis 185 of PCA coefficient and differential expression analysis (see Methods; Supplementary 186 Tables S10 and S11; Supplementary Figure S9 ). Pathway enrichment analysis was most 187 significant for evidence of epithelial-mesenchymal transition (EMT) in the C1 tumors, with 188 concordant loss of E-cadherin (CDH1) and upregulation of CXCL14, both prognostic 189 biomarkers in diverse other cancers ( Supplementary Table S12 , Figure 2d -f) [25] [26] [27] [28] [29] [30] [31] [32] . The C1 190 and C2 tumors were further distinguished by significant dysregulation of proliferation, 191 PRC2 activity and embryonic stem cell transcriptional programmes (Supplementary Table  192 S13). Hox genes constituted a notable proportion of the transcripts distinguishing the two 193 anaplastic meningioma subgroups, largely underpinning the significance of pathways 194 involved in tissue morphogenesis. Furthermore, differentially methylated genes were also 195 significantly enriched for Hox genes, with pathway analysis results corroborating the main 196 biological themes emerging from transcriptome analysis (Supplementary Tables S14 and 197 S15). 198 199
Comparison of the anaplastic and benign meningioma transcriptome 200
Previous studies investigating the relationship between meningioma WHO grade and 201 gene expression profiles have included few anaplastic tumors 33,34 . We therefore extended 202 our analysis to include published RNA sequences from 19 benign grade I meningiomas. 203
External data was processed using our in-house pipeline with additional measures taken 204 to minimise batch effects (see Methods and Supplementary Tables S16 and S17). anaplastic meningioma subgroups, we noted significant overlap between genes 209 differentially expressed between grades and between C1 and C2 tumors (hypergeometric 210 distribution P = 5.084E-09). In keeping with this finding, formal pathway analysis identified 211 significant dysregulation of stemness, proliferation, EMT and PRC2 activity 212 (Supplementary Tables S18 and S19). The most significantly dysregulated pathways also 213 included TGF-beta, Wnt and integrin signalling, mediators of invasion and mesenchymal 214 differentiation that are normally in part controlled by NF2 and other Hippo pathway 215 members 15,16,35-37 . Yes-associated protein 1 (Yap1), a cornerstone of oncogenic Hippo 216 signalling, is frequently overexpressed in cancer and synergises with Wnt signalling to 217 induce EMT 15,37-39 . YAP1 was upregulated in anaplastic tumors (log 2 fold change = 2.18, 218 FDR = 0.0062) along with MYL9 (log 2 fold change = 6.25, FDR = 3.76E-18), a key 219 downstream effector essential for Yap1-mediated stromal reprogramming ( Figure 3c ) 38 . 220
Additionally, the anaplastic tumors demonstrated further upregulation of major growth 221 factor receptor and kinase circuits previously implicated in meningioma pathogenesis, 222 notably epidermal growth factor receptor (EGFR), insulin-like growth factor (IGFR), 223 vascular endothelial growth factor receptor (VEGFR) and mTOR complex 1 (mTORC1) 224 kinase complex [40] [41] [42] [43] [44] [45] . constitute the main genomic distinction between anaplastic and lower grade 235 meningiomas 8,10 . SWI/SNF acts as a tumor suppressor in many cell types by 236 antagonising the chromatin modifying Polycomb repressive complex 2 (PRC2) 46-48 . 237 Deleterious SWI/SNF mutations unfetter PRC2 activity with profound consequences for 238 primitive developmental pathways frequently co-opted during oncogenesis 48, 49 . SWI/SNF 239 inactivation is associated with a stem cell-like phenotype and poor outcomes in diverse 240 cancer types 50-54 . 241
242
Although anaplastic tumors resist meaningful classification based on driver mutation 243 patterns, unbiased transcriptional profiling revealed two biologically distinct subgroups 244 with dramatically divergent survival outcomes. This finding is emblematic of the limitations 245 of histopathological grading as a risk stratification system for meningioma 1,3,4,13,55 . 246
Interestingly, all SWI/SNF mutations were exclusively identified in the poor prognosis (C1) 247 subgroup (P = 0.016, Fisher's exact test). C1 tumors were further characterised by 248 transcriptional signatures of PRC2 target activation, stemness, proliferation and 249 mesenchymal differentiation. These findings were in part underpinned by differential 250 expression of Hox genes. Acquisition of invasive capacity and stem cell traits are 251 frequently co-ordinately dysregulated in cancer, often through subversion of Hox gene 252 programmes integral to normal tissue morphogenesis [56] [57] [58] . Hox genes have a central role 253 in orchestrating vertebrate development and act as highly context-dependent oncogenes 254 and tumor suppressors in cancer 57,59 . Several of the most starkly upregulated Hox genes 255 in the C1 tumors consistently function as oncogenes across a range of solid and 256 haematological malignancies, including HOTAIR, HOXB7, HOXA4, HOXA-AS2, 257 HOXC11, and NKX2-2 57,60-70 . Like many long non-coding RNAs (lncRNA), HOTAIR and 258 HOXA-AS2 modulate gene expression primarily by interacting directly with chromatin 259 11 remodelling complexes, exerting oncogenic activity by recruiting PRC2 to target 260 genes 60,62,69-73 . HOXA-AS2 has been shown to mediate transcriptional repression of the 261 tumor suppressor gene CDKN2A (p16 INK4A ), loss of which is associated with poor 262 meningioma survival 23,24,60,69,70 . Given the antagonistic relationship between the SWI/SNF 263 and PRC2 chromatin regulators, deleterious SWI/SNF mutations and overexpression of 264 lncRNAs known to mediate PRC2 activity emerge as potentially convergent mechanisms 265 underpinning the differences between C1 and C2 tumors 49 . 266
267
In the context of recent studies of lower grade meningiomas, our findings raise the 268 possibility that the balance between PRC2 and SWI/SNF activity may have broader 269 relevance to meningioma pathogenesis. Compared to grade I tumors, atypical 270 meningiomas are more likely to harbor SMARCB1 mutations and large deletions 271 encompassing chromosomes 1q, 6q and 14q. Notably, these genomic regions 272 encompass ARID1A and several other SWI/SNF subunit genes. Both SMARCB1 273 mutations and the aforementioned copy number changes were associated with 274 epigenetic evidence of increased PRC2 activity, differential Homeobox domain 275 methylation, and upregulation of proliferation and stemness programmes in the atypical 276
tumors. 277 278
The extent to which SWI/SNF depletion plays a role in lower grade meningiomas may be 279 therapeutically relevant. Diverse SWI/SNF mutated cancers exhibit dependence on both 280 catalytic and non-catalytic functions of EZH2, a core subunit of PRC2 74-76 . Several EZH2 281 inhibitors are in development with promising initial clinical results 77 . Other modulators of 282 PRC2 activity, including HOTAIR, may also be relevant therapeutic targets 78,79 . 283 Furthermore, growing recognition of the relationship between EMT and resistance to 284 conventional and targeted anti-cancer agents has profound implications for rational 285 12 integration of treatment approaches 80,81 . Notably, EGFR inhibition has yielded 286 disappointing response rates in meningioma 41, 82 . A mesenchymal phenotype is strongly 287 associated with resistance to EGFR inhibitors in lung and colorectal cancer 80,81,83-85 . 288 Combining agents that abrogate EMT with other therapies is a promising strategy for 289 addressing cell-autonomous and extrinsic determinants of disease progression and may 290 warrant further investigation in meningioma 80, 86 . 291
292
This study has revealed prognostically significant anaplastic meningioma subgroups and 293 identified potentially actionable alternations in SWI/SNF genes and other therapeutically 294 tractable targets. However, a substantially larger series of tumors, ideally nested in a 295 prospective multicentre observational study, will be required to expand upon our main 296 findings and explore mechanistic and therapeutic ramifications of meningioma diversity. Figure S10 ). Analysis of WGS and RNA sequencing data identified an expressed gene 315 fusion, NAB2-STAT6. This fusion is pathognomonic of meningeal hemangiopericytoma, 316 now classified as a separate entity, solitary fibrous tumors 87-89 . We therefore excluded 317 three samples from this tumor from further study. A second sample (PD23354a), 318 diagnosed as an anaplastic meningioma with papillary features, was found to have a 319 strong APOBEC mutational signature as well as an EML4-ALK gene fusion (exon 6 320 EML4, exon 19 ALK) (Supplementary Figure S11) (ArrayExpress: GSE85133) 8 . Reads were then processed using STAR and HTseq as 358 were further annotated according to whether they involved a kinase or known oncogene 366 and whether they occurred near known fragile sites or rearrangement break points 96 367
( Supplementary Table S5 ). 368 369
Differential gene expression and pathway enrichment analysis 370
The DESeq2 R package was used for all differential gene expression analyses 97,98 . 371
DESeq2 uses shrinkage estimation of dispersion for the sample-specific count 372 normalization and subsequently applies a linear regression method to identify differentially 373 expressed genes (DEGs) 97, 98 . 374 revealed evidence of laboratory batch effects, which we mitigated with two 376 batch-correction methods: RUVg and PEER 99,100 . RUVg estimates the factor attributed to 377 spurious variation using control genes that are assumed to have constant expression 378 across samples 101-103 . We selected control genes (RPL37A, EIF2B1, CASC3, IPO8, 379 MRPL19, PGK1 and POP4) on the basis of previous studies of suitable control genes for 380 transcript-based assays in meningioma 104 . PEER ('probabilistic estimation of expression 381 residuals') is based on factor analysis methods that infer broad variance components in 382 the measurements. PEER can find hidden factors that are orthogonal to the known 383 covariates. We applied this feature of PEER to remove additional hidden effect biases. 384
The final fitted linear regression model consists of the factor identified by RUVg method 385 that represents the unwanted laboratory batch effect and 13 additional hidden factors 386 found by PEER that are orthogonal to the estimated laboratory batch effect. Using this 387 approach we were able to reduce the number of DEGs from more than 18000 to 8930, of 388 which <4,000 are predicted to be protein-coding. 389 To identify biological pathways differentially expressed between meningioma grades and 390 anaplastic meningioma subgroups we applied a functional class scoring algorithm using a 391 collection of 461 published gene sets mapped to 10 canonical cancer hallmarks 392
( Supplementary Table S21 ) 56 ,105-109 . We further corroborated these findings with a more 393 general Gene Ontology (GO) pathway analysis 110 . 394 395
Identification of 6 transcripts recapitulating anaplastic meningioma clusters 396
Mapped RNA sequencing reads were normalised using the regularised logarithm (rlog) 397 function implemented by the DESeq2 package 97,98 . PCA was performed using the top 500 398 most variably expressed transcripts and the prcomp function (R stats package) 111 . Given 399 that primary component 1 (PC1) was the vector most clearly distinguishing the closely 400 top 50 transcripts with the highest absolute PC1 coefficients. We then identified the subset 402 that overlapped with the most significantly differentially expressed genes (absolute log 2 403 fold change > 4 and adjust p-value < 0.0001) between i) the C1 and C2 anaplastic 404 meningioma subgroups and ii) the C1 anaplastic meningiomas and the 19 grade I tumors 405
(Supplementary Tables S10 and S17). Iteratively reducing the number of PC1 406 components identified the minimum number of transcripts that recapitulated segregation 407 of C1 and C2 tumors upon unsupervised hierarchical clustering and PCA (Supplementary 408 Table S11 ; Supplementary Figure S9 ). Structural variants were called using a bespoke algorithm, BRASS (BReakpoint 418 AnalySiS) (https://github.com/cancerit/BRASS) as previously described 115 . 419
The ascatNGS algorithm was used to estimate tumor purity and ploidy and to construct 420 copy number profiles from whole genome data 116 . 421 422
Identification of cancer genes based on the impact of coding mutations 423
To identify recurrently mutated driver genes, we applied a dN/dS method that considers 424 the mutation spectrum, the sequence of each gene, the impact of coding substitutions 425 (synonymous, missense, nonsense, splice site) and the variation of the mutation rate Supplementary Tables S22 and S23) 119 . 442
Copy number data was analysed for homozygous deletions encompassing tumor 443 suppressor genes and for oncogene amplifications exceeding 5 or 9 copies for diploid 444 and tetraploid genomes, respectively. Only focal (<1Mb) copy number variants meeting 445 these criteria were considered potential drivers. Additional truncating events (disruptive 446 rearrangement break points, nonsense point mutations, essential splice site mutations 447 and out of frame indels) in established tumor suppressors were also flagged as potential 448 drivers. Only rearrangements with breakpoints able to be reassembled at base pair 449 resolution are included in this dataset. were normalized under R statistical environment using the Illumina normalization method 470 developed under the minfi package (v1.19.10). Normalized intensities were then used to 471 calculate DNA methylation levels (beta values). Then, we excluded from the analysis the 472 positions with background signal levels in methylated and unmethylated channels 473 (p>0.01). Finally we removed probes with one or more single nucleotide polymorphisms 474 finally considered. We observed high levels of methylation for CREBBP in the majority of 489 tumor samples, however, similar patterns were manifest in normal tissue controls, hence 490 CREBBP hypermethyation does not appear to be a feature of oncogenesis in these 491
samples. 492 493

Mutational signature analysis 494
Mutational signature extraction was performed using the nonnegative matrix factorization 495 (NNMF) algorithm 11 . Briefly, the algorithm identifies a minimal set of mutational signatures 496 that optimally explains the proportions of mutation types found across a given mutational 497 catalogue and then estimates the contribution of each identified signature to the mutation 498 spectra of each sample. 499 500
Patient survival analysis 501
The Kaplan-Meier method was used to analyze survival outcomes by the log-rank 502
Mantel-Cox test, with hazard ratio and two-sided 95% confidence intervals calculated 503 using the Mantel_Haenszel test (GraphPad Prism, ver 7.02). Overall survival data from 504 21 time of first surgery for each anaplastic meningioma within gene-expression defined 505 subgroups 1 and 2 was collected and used to plot a Kaplan-Meier survival curve. 506 507
Data availability 508
All sequencing data that support the findings of this study have been deposited in the 509 European Genome-Phenome Archive and are accessible through the accession numbers 510 EGAS00001000377, EGAS00001000828, EGAS00001000859, EGAS00001001155 and 511 EGAS00001001873. All other relevant data are available from the corresponding author 512 on request. 513 514
Supplementary Discussion 515
A hypermutator anaplastic meningioma with a haploid genome 516 One primary anaplastic meningioma resected from an 85-year old female (PD23359a) 517 had a hypermutator phenotype, with 27,332 point mutations and LOH across nearly its 518 entire genome (Supplementary Figure S12 ; Supplementary Table S24 ). Independent 519 pathological review confirmed the original diagnosis of anaplastic meningioma, and 520 transcriptome analysis confirmed that this tumor clustered appropriately with the rest of 521 the cohort (Figure 3a,b) . The majority of the mutations were substitutions, 72% of which 522 were C>T transitions. We identified two deleterious mutations in DNA damage repair 523 mediators: a TP53 p.R248Q missense mutation and a homozygous truncating variant in 524 the mismatch repair gene MSH6 (p.L1330Vfs*9). Despite the latter finding, mutational 525 signatures analysis was dominated by signature 1, with no evidence of signatures 526 typically associated with defects in homologous recombination, mismatch repair or POLE 527 activity (signatures 3, 6, 10, 15, 20 or 26). The copy number profile is most consistent with 528 this tumor having first undergone haploidization of its genome, with the exception of 529 chromosomes 7, 19 and 20, followed by whole genome duplication (Supplementary 530 22 Figure S12 ). Of note, several important oncogenes are located on chromosome 7, 531 including EGFR, MET and BRAF. Widespread LOH has been described in a significant 532 proportion of oncocytic follicular thyroid cancers where preservation of chromosome 7 533 heterozygosity has also been observed 121 Centre. We are grateful to the patients who enabled this study and to the clinical teams 847 coordinating their care. 
